The online ‘sex peptide’ market is growing. So are the health risks
Industry Buzz
There are RCTs demonstrating bremalanotide’s efficacy in some cases of hypoactive sexual desire disorder in perimenopause. However, there is no reason to believe that each melanocortin-related or ‘sex-wellness’ peptide being marketed online has similar scientific evidence supporting its claims.
—Kyle Hoedebecke, MD
Patients are increasingly asking about peptides marketed for libido, erectile function, and fertility, often after encountering them through podcasts, social media, or direct-to-consumer platforms. For physicians, the challenge is separating approved therapies from loosely regulated products marketed under the broader “sexual wellness” peptide umbrella.
Related: ‘Horny peptides’ go mainstream: Here’s what patients may get wrongBremelanotide, or PT-141, has been FDA-approved since 2019,[] but interest accelerated in early 2026 as the drug and other peptides entered mainstream conversations about sexual performance. In March, PT-141 was discussed on The Joe Rogan Experience, where the conversation focused largely on personal experiences rather than clinical indications, contraindications, or evidence.[]
The American Urological Association noted in an April 2026 review that enthusiasm for sexual health peptides is increasingly being fueled by podcasters, influencers, online forums, and word of mouth. With relatively few new options for male sexual dysfunction, physicians may be seeing more patients considering alternatives whose evidence, sourcing, and safety profiles vary considerably.[]
The peptide DTC market
In July 2026, an FDA advisory panel reviewed seven unapproved peptides for possible inclusion on the 503A bulk drug list. The discussion did not concern sexual health peptides, but it came as peptide use was receiving broader regulatory attention.[]
The broader peptide market includes Melanotan II, kisspeptin, oxytocin, and several growth-hormone-related compounds.
Furthermore, direct-to-consumer telehealth has made peptide access easier for patients. Platforms such as Hone Health list compounded PT-141 as a sexual health treatment for men. “I am concerned that many social media outlets blur the lines between a product approved by the FDA as a medication and products being sold online under generic terms such as ‘libido’ or ‘erectile,’” Robert Thompson, DO, MS, CPE, FAAFP, tells MDLinx.
Kyle Hoedebecke, MD, notes, “I would draw a distinction between FDA-authorized peptide medicines and the numerous (and mostly unregulated) peptides marketed online. There are randomized clinical trials demonstrating bremalanotide’s efficacy in some cases of hypoactive sexual desire disorder (HSDD) in perimenopause. However, there is no reason to believe that each melanocortin-related or ‘sex-wellness’ peptide being marketed online has similar scientific evidence supporting its claims.”
The sourcing problem
The FDA states that it does not review compounded drugs for safety, efficacy, or quality before they are marketed, Dr. Hoedebecke notes.[] “Uncertainty regarding compound or internet-sourced products is the largest problem. Specifically, product identity, concentration, sterility, dosing accuracy and clinical effectiveness may have gone through less than the same level of pre-market evaluation as an approved drug,” he adds.
Related: This looksmaxxer's drug & peptide regimen is a medical nightmareAdverse events
“Compounding pharmacies do not have their products reviewed by the FDA prior to marketing. Therefore, they are not required to prove efficacy, safety, or quality,” Dr. Thompson says.
Safety and evidence vary widely across sexual health peptides. According to family medicine physician James Lyons, MD, “cardiovascular risks and tolerance” are recognized adverse events of peptides such as PT-141. “Bremelanotide can increase blood pressure temporarily, decrease heart rate, and produce nausea, flushing, headaches, and hyperpigmentation.”
The FDA contraindicates use in uncontrolled hypertension or known cardiovascular disease.[] “I would never suggest PT-141 as a casual ‘wellness’ injection,” Dr. Lyons adds.
Melanotan II has been associated with severe nausea, yawning, flushing, and priapism.[] Evidence for kisspeptin and oxytocin in sexual dysfunction remains limited.
What patients are reporting about PT-141 for sexual health
One Reddit user (@Ray-Shoestring) described the effect in striking terms, writing, “[PT-141 is] 300x at least better than Viagra or Cialis.” But the sexual health boost is not without it's uncomfortable side effects. Consider the following:
Benefits: Users reported stronger erections, increased libido, longer-lasting effects, and benefit even after sildenafil or tadalafil had failed.
Nausea: The most common complaint among users, sometimes severe enough to limit activity.
Flushing/Overheating: Several users described facial flushing or feeling unusually hot.
Prolonged Erections: Some reported erections that lasted too long or became uncomfortable, raising priapism concerns.
Fatigue: Sleepiness and feeling “knocked out” were also reported.
Unpredictable Timing: Effects could take hours to appear and sometimes lasted into the next day.
Variable Response: Some users described dramatic benefit; others saw little or inconsistent effect.
DIY Dosing Risks: Commenters described online sourcing, self-reconstitution, dose experimentation, and combining PT-141 with PDE5 inhibitors.